Galmed Pharmaceuticals Ltd
Galmed Stock Rose Over 26% on ‘Overweight’ Rating
Today, Galmed Pharmaceuticals (GLMD) soared as Cantor Fitzgerald initiated coverage on the stock with an “overweight” rating and a target price of $59.
Why Galmed Pharmaceuticals Stock Rose 151% on June 12
Galmed Pharmaceuticals stock rose 151.3% on June 12. The stock closed at $17.59, which is a 387% increase from its 52-week low of $3.61 on February 14.
Which Gilead Sciences Portfolio Could Give a Long-Term Boost
NASH is a chronic disease related to steatosis wherein fat accumulates in the liver and can lead to inflammation, progressive fibrosis, and cirrhosis.